摘要
目的探讨巨噬细胞移动抑制因子(macrophagemigration inhibitory factor,MIF)在前列腺癌(prostate cancer,Pca)中的发生、发展的作用,为前列腺癌的诊断及治疗提供新途径。方法采用免疫组化方法检测40例良性前列腺增生症(BPH)和59例前列腺癌(Pca)组织中MIF的表达。结果Pca组织MIF阳性表达率为84.7%(46/58),明显高于BPH组30%(P<0.05);MIF在Pca组织中的表达水平与其病理分级呈正相关(P<0.05);MIF阳性表达的肿瘤复发快、易转移、预后差。结论MIF与Pca组织学分级、恶性程度和预后密切相关,是检测Pca的较好分子标志物,适时检测MIF的表达可作为判断Pca生物学行为及预后的重要参考价值。
Aim To investigate the significance of MIF in carcinogenesis, progression and angiogenesis of prostate carcinoma, and to provide an approach for the diagnosis and treatment of the tumor. Methods The expression of MIF in 40 benign prostate hyperplasia（BPH） and 59 prostate carcinoma （Pca） was examined with immunohistochemistry. Results The positive expression rates of MIF in 60 cases of Pca and BPH were 84.7 % and 30% respectively. The expression levels of MIF in prostatic carcinoma was much higher than that in BPH （ P 〈 0.05 ） ; the positive correlation was noted between MIF expression the tumor pathologic grades （ P 〈 0.05 ）. Tumors with high level of MIF positive recurred earlier and had a greater risk of stage progression than . those with low level of MIF negative. Conclusion This study indicates that MIF is closely related to the histopathological grading and the tumor differentiation and prognosis of Pca. MIF is good molecular marker of Pca. The detection of MIF may serve as an important referrence to estimate the biological behavior and prognosis of Pca.
出处
《安徽医药》
CAS
2009年第11期1361-1363,共3页
Anhui Medical and Pharmaceutical Journal
